ASH: Beam’s Base Editor Efficacy In Sickle Cell Disease Holds Up

Next-Gen Program Aims To ESCAPE Busulfan Conditioning

Base editing may give Beam a competitive edge in sickle cell disease (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from Conferences